Download PDF
Der Klinikarzt 2010; 39(3): 140-146
DOI: 10.1055/s-0030-1253323
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Rolle der Inflammation in der Atherosklerose – Ein Update

The role of inflammation in atherosclerosis – An updateMahir Karakas1 , Wolfgang Koenig1
  • 1Zentrum für Innere Medizin, Klinik für Innere Medizin II – Kardiologie, Angiologie, Pneumologie, Sport- und Rehabilitationsmedizin, Universitätsklinikum Ulm
Further Information

Publication History

Publication Date:
29 March 2010 (online)

Also available at
    Permissions and Reprints

Die Atherosklerose zeigt typische Charakteristika eines inflammatorischen Prozesses, sowohl lokal in der Gefäßwand als auch systemisch. Verschiedene klinische Krankheitsbilder, die mit einer systemischen Inflammation einhergehen, sind gehäuft mit atherosklerotischen Komplikationen assoziiert. In prospektiven Studien konnte ein Zusammenhang zwischen erhöhten Plasma-/Serumkonzentrationen sensitiver Marker, einer systemischen Inflammation und dem Auftreten kardiovaskulärer Ereignisse gezeigt werden. Hier ist insbesondere das C-reaktive Protein zu nennen, welches kürzlich zur verbesserten Risikostratifizierung Eingang in die kanadischen Leitlinien zur kardiovaskulären Prävention gefunden hat. Nach indirekten positiven Hinweisen aus der JUPITER-Studie wird die Inflammationshypothese derzeit mit spezifischeren antiinflammatorischen Substanzen in großen randomisierten klinischen Studien getestet, um das immer noch hohe residuale Risiko kardiovaskulärer Ereignisse bei Patienten mit Atherosklerosemanifestationen trotz optimaler Polypharmakotherapie weiter zu senken.

Atherosclerosis shows typical features of a local and systemic inflammatory process. Thus, many diseases with underlying chronic systemic inflammation are associated with atherosclerotic complications, in particular coronary heart disease. Prospective observational studies identified various sensitive biomarkers of inflammation as predictors of cardiovascular risk, in apparently healthy individuals as well as in patients with manifest atherosclerosis. Among them, C-reactive protein, measured by high-sensitivity assays, has received widespread attention and was recently included in the Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. After indirect positive evidence from the JUPITER study, the inflammatory hypothesis is presently being tested in large randomized clinical trials with new, more specific anti-inflammatory compounds, with the intention to translate advances in basic science into clinical practice.

Key words

Inflammation - atherosclerosis - innate and adaptive immunity - coronary heart disease

Literatur

  • 1 Ross R.. Atherosclerosis – An Inflammatory Disease.  N Engl J Med. 1999;  340 115-126
    CrossrefPubMedGoogle Scholar
  • 2 Libby P, Ridker PM, Maseri A.. Inflammation and atherosclerosis.  Circulation. 2002;  105 1135-1143
    CrossrefPubMedGoogle Scholar
  • 3 Virchow R.. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre, 3. Auflage.. Berlin: Verlag von August Hirschwald; 1862: 353
    Google Scholar
  • 4 Witztum J, Steinberg D.. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?.  Trends Cardiovasc Med. 2001;  11 93-102
    CrossrefPubMedGoogle Scholar
  • 5 Meisinger C, Loewel H, Mraz W, Koenig W.. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study.  Eur Heart J. 2005;  26 271-278
    CrossrefPubMedGoogle Scholar
  • 6 Gerszten RE, Garcia-Zepeda EA, Lim Y-C et al.. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.  Nature. 1999;  398 718-723
    CrossrefPubMedGoogle Scholar
  • 7 Ichikawa K, Yoshinari M, Iwase M et al.. Advanced glycation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients.  Atherosclerosis. 1998;  136 281-287
    CrossrefPubMedGoogle Scholar
  • 8 Ichikawa K, Nakagawa K, Hirano K, Sueishi K.. The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition.  Pathol Res Pract. 1996;  192 224-232
    PubMedGoogle Scholar
  • 9 Shih PT, Brennan M-L, Vora DK et al.. Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet.  Circ Res. 1999;  84 345-351
    PubMedGoogle Scholar
  • 10 Raines EW, Ross R.. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis.  Br Heart J. 1993;  69 30-37
    CrossrefPubMedGoogle Scholar
  • 11 Hansson GK.. Inflammation, atherosclerosis, and coronary artery disease.  N Engl J Med. 2005;  352 1685-1695
    CrossrefPubMedGoogle Scholar
  • 12 Libby P.. Current concepts of the pathogenesis of the acute coronary syndromes.  Circulation. 2001;  104 365-372
    CrossrefPubMedGoogle Scholar
  • 13 Hartvigsen K, Chou MY, Hansen LF et al.. The role of innate immunity in atherogenesis.  J Lipid Res. 2009;  50 (S 01) 388-393
    CrossrefPubMedGoogle Scholar
  • 14 Andersson J, Libby P, Hansson GK.. Adaptive immunity and atherosclerosis.  Clin Immunol. 2010;  134 33-46
    CrossrefPubMedGoogle Scholar
  • 15 Koenig W, Khuseyinova N.. Biomarkers of atherosclerotic plaque instability and rupture.  Arterioscler Thromb Vasc Biol. 2007;  27 15-26
    CrossrefPubMedGoogle Scholar
  • 16 The Emerging Risk Factors Collaboration. . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.  Lancet. 2010;  375 132-140
    CrossrefPubMedGoogle Scholar
  • 17 Garza CA, Montori VM, McConnell JP et al.. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.  Mayo Clin Proc. 2007;  82 159-165
    CrossrefPubMedGoogle Scholar
  • 18 Karakas M, Koenig W.. Phospholipases A2 as a therapeutic target for atherosclerosis.  Clin Lip. 2010;  5 57-69
    PubMedGoogle Scholar
  • 19 Wenzel U, Wolf G.. Blood pressure independent effects of antihypertensive agents.  Internist. 2005;  46 548-556
    CrossrefPubMedGoogle Scholar
  • 20 Urbauer E, Joukhadar C.. Non-lipid effects of statins: myth or fact?.  Wien Med Wochenschr. 2003;  153 244-249
    CrossrefPubMedGoogle Scholar
  • 21 Solomon DH, Karlson EW, Rimm EB et al.. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.  Circulation. 2003;  107 1303-1307
    CrossrefPubMedGoogle Scholar
  • 22 Choi HK, Hernan MA, Seeger JD et al.. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.  Lancet. 2002;  359 1173-1177
    CrossrefPubMedGoogle Scholar
  • 23 Jacobsson LT, Turesson C, Nilsson JA et al.. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.  Ann Rheum Dis. 2007;  66 670-675
    CrossrefPubMedGoogle Scholar
  • 24 Edwards CJ.. Myocardial Infarction in rheumatoid arthritis: the effects of DMARDs and prednisolone.  (Abstract). Arthritis Rheum. 2008;  56 (S 09)
    PubMedGoogle Scholar
  • 25 Ridker PM, Danielson E, Fonseca FA et al.. Rosuvastatin to prevent events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 2195-2207
    CrossrefPubMedGoogle Scholar
  • 26 Genest J, McPherson R, Frohlich J et al.. 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendation.  Can J Cardiol. 2009;  25 567-579
    CrossrefPubMedGoogle Scholar
  • 27 Lundberg AM, Hansson GK.. Innate immune signals in atherosclerosis.  Clin Immunol. 2010;  134 5-24
    CrossrefPubMedGoogle Scholar

Korrespondenz

Prof. Dr. med. Wolfgang Koenig

FRCP, FESC, FAHA, FACC Universitätsklinikum Ulm Zentrum für Innere Medizin Klinik für Innere Medizin II

Albert-Einstein-Allee 23

89081 Ulm

Fax: 0731/500-45021

Email: wolfgang.koenig@uniklinik-ulm.de

      >